Table 2 Combining lipid-targeted therapies with chemotherapy and targeted therapy
From: Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics
Target | Treatment | Phase | Tumor type | Combined treatment | Reference |
|---|---|---|---|---|---|
CD36 | JC63.1 (anti-CD36) | In vivo | Breast cancer | Lapatinib (HER2/EGFR inhibitor) | [231] |
FA6.152 (anti-CD36) | In vivo | Leukemia | Ara-C | [232] | |
SSO (CD36 inhibitor) | In vivo | Leukemia | Ara-C, Doxorubicin, Etoposide, SN-38, Irinotecan, Dasatinib | [233] | |
FABPs | SBFI-102/103 (FABP5 inhibitor) | In vivo | Prostate cancer | Taxane | [236] |
BMS309403 (FABP4 inhibitor) | In vivo | Ovarian cancer | Carboplatin | [237] | |
FATPs | Lipofermata (FABP2 inhibitor) | In vivo | Melanoma | PLX4720 (BRAFi) PD0325901 (MEKi) | [238] |
ACLY | SB-204990 | In vivo | Melanoma | Vemurafenib (BRAFi) | [239] |
In vitro | Ovarian cancer | Cisplatin | [240] | ||
ACC | TOFA | In vivo | HNSCC | Cetuximab | [241] |
ND-646 | In vivo | NSCLC | Carboplatin | [242] | |
ND-654 | In vivo | HCC | Sorafenib | [243] | |
FASN | TVB-2640 | Phase II | HER2+ Breast cancer | Taxane or trastuzumab | NCT03179904 |
Phase II | Astrocytoma | Bevacizumab | NCT03032484 [258] | ||
Phase III | Glioblastoma | Bevacizumab | NCT05118776 | ||
Phase I | NSCLC, ovarian, and breast cancer | Taxane | NCT02223247 [257] | ||
Orlistat | In vivo | Pancreatic cancer | Gemcitabine | [249] | |
In vivo | Prostate cancer | Radiotherapy | [247] | ||
In vivo | Ovarian cancer | Cisplatin | [248] | ||
In vitro | HCC | Sorafenib | |||
In vivo | NSCLC | Gefitinib (EGFRi) | [250] | ||
C75 | In vivo | Breast cancer | Cetuximab | [319] | |
In vivo | Gastrointestinal stromal tumors (GIST) | Imatinib | [320] | ||
In vivo | Breast cancer | CYH33 (PI3Ki) | [253] | ||
TVB-3664 | In vivo | HCC | Cabozantinib, Sorafenib | [251] | |
In vivo | Lung adenocarcinoma | MRTX849 (KRASi) | [252] | ||
TVB-3166 | In vivo | Ovarian, prostate and pancreatic cancer | Taxane | [254] | |
Fasnall | In vivo | HER2+ Breast cancer | Carboplatin | [255] | |
AZ12756122 | In vitro | NSCLC | Osimertinib | [256] | |
SCD | A939572 | In vitro | Glioblastoma | Temozolomide | [262] |
In vivo | ccRCC | Temsirolimus (mTORi) | [261] | ||
SSI-4 | In vivo | HCC | Sorafenib | [263] | |
g-PPT | In vivo | NSCLC | Gefitinib | [264] | |
MF-438 | In vitro | Melanoma | Vemurafenib, Binimetinib | [260] | |
In vitro | Lung cancer | Cisplatin | [265] | ||
HMGCR | Simvastatin | Phase II | NSCLC | Gefitinib | NCT00452244 [275] |
Phase II | Breast cancer | Fluorouracil, adriamycin, and cyclophosphamide | NCT04418089 [276] | ||
Phase III | Prostate cancer | ADT | NCT03127631 [278] | ||
In vitro | Endometrial cancer | Metformin | [271] | ||
In vivo | Renal cell carcinoma | Everolimus | [270] | ||
In vitro | Glioblastoma | Temozolomide | [272] | ||
Lovastatin | In vivo | Gallbladder cancer | Cisplatin | [273] | |
In vitro | Nasopharyngeal carcinoma | Cisplatin, cyclophosphamide, doxorubicin and paclitaxel | [274] | ||
SREBP | Fatostatin | In vivo | Melanoma | Vemurafenib | [266] |
In vivo | Prostate cancer | Taxane | [321] | ||
Betulin | In vivo | HCC | Sorafenib | [267] | |
ChoK | MN58b TCD-717 | In vivo In vitro | Colorectal cancer, PDAC | 5-flurouracil | |
COX | Aspirin | Phase II | ER+ breast cancer | ACT | NCT04038489 |
Sulindac | Phase II | Colorectal cancer | Erlotinib | NCT01187901 | |
CPT | Etomoxir | In vivo | Leukemia | Ara-C | [284] |
In vivo | Glioblastoma | Temozolomide | [322] | ||
In vivo | HCC | Antiangiogenic drug | [287] | ||
In vivo | Gastric cancer | 5-fluorouracil | [285] | ||
In vivo | Nasopharyngeal carcinoma | Radiotherapy | [286] | ||
In vitro | Breast cancer | Radiotherapy | [323] | ||
Perhexiline | In vivo | Colorectal and gastric cancer | Oxaliplatin | [14] | |
In vivo | PDAC | Gemcitabine | [289] | ||
In vivo | Ovarian cancer | Cisplatin | [290] | ||
In vitro | Breast cancer | Paclitaxel | [291] | ||
ST1326 | In vivo | Leukemia | ABT199 (Bcl-2 inhibitor) | [324] | |
DGAT | PF-06424439 | In vitro | Colorectal cancer | 5-fluorouracil | [297] |
In vitro | Breast cancer | Cisplatin, radiotherapy | |||
ACAT | Avasimibe | In vivo | Leukemia | Imatinib | [325] |
In vivo | Breast cancer | Doxorubicin | [326] | ||
In vivo | Melanoma | Paclitaxel | [303] | ||
In vivo | PDAC | Gemcitabine | [304] | ||
In vitro | Biliary tract cancer | Gemcitabine | [305] |